The most detailed look ever at data for rosiglitazone, the diabetes drug marketed by GlaxoSmithKline (GSK) as Avandia, shows the one-time blockbuster significantly raises the overall risk of heart problems or cardiovascular death, calling attention to the need for more transparency in data collection.
The most detailed look ever at data for rosiglitazone, the diabetes drug marketed by GlaxoSmithKline (GSK) as Avandia, shows the one-time blockbuster significantly raises the overall risk of heart problems or cardiovascular death, calling attention to the need for more transparency in data collection.
Rosiglitazone is among the most controversial drugs in history. Approved in 1999, sales topped $2.5 billion a year when a 2007 study in The New England Journal of Medicine (NEJM) linked the type 2 diabetes treatment to heart attacks and early death, prompting sales restrictions and lawsuits and, ultimately, an FDA guidance that changed the way diabetes and cardiovascular drugs are evaluated. This paved the way for sodium glucose co-transporter 2 (SGLT2) inhibitors, which appear to be all-purpose weapons against diabetes, heart failure, renal decline, and, possibly, obesity.
Today’s findings, appearing in The BMJ, examine results from more than 130 trials involving 48,000 patients, with each comparing rosiglitazone with a control for at least 24 weeks. For 33 trials, the researchers gained access to individual patient-level data, instead of relying on summary data from clinical trial registries, which may or may not include all adverse events. The team from Yale launched the study after GSK made independent patient-level data available, years after the drug’s patent expired in 2012.
For the data pool using individual patient data, rosiglitazone was associated with a 33% increased risk of a composite of cardiovascular events—heart attack, heart failure, cardiovascular death, and noncardiovascular death (odds ratio [OR], 1.33; 95% CI, 1.09-1.61). Secondary outcomes, for each elements of the composite, were as follows:
When results for trials without individual patient data were included, the results were not as strong. But the heart failure finding stands out, given what has occurred in the diabetes therapy market over the past decade.
The study authors said in a statement that the findings show why sharing individual patient data from different sources matters. "Our study suggests that when evaluating drug safety and performing meta-analyses focused on safety, [individual patient data] might be necessary to accurately classify all adverse events," they write. "By including these data in research, patients, clinicians, and researchers would be able to make more informed decision about the safety of interventions."
Rosiglitazone was approved based on its effectiveness at lowering glycated hemoglobin (A1C). After the link to heart attacks was published in NEJM, other studies refuted this finding, but the controversy lingered. As newer drug classes appeared, rosiglitazone never regained its popularity, particular after SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists were shown to have cardioprotective effects.
In 2008, in the wake of the rosiglitazone incident, the FDA issued a guidance that said showing a diabetes drug could lower A1C was not enough. Manufacturers would be required to conduct large, expensive cardiovascular outcomes trials to demonstrate that the drugs did not cause adverse events—namely heart attacks and strokes.
These trials were designed simply to show that newer drug classes were safe—that they would not cause harm. But the surprise came in 2015, when a trial showed that the mechanisms of SGLT2 inhibitors had a positive effect on heart failure, even though this was a initially a secondary outcome. In response, manufacturers launched dedicated heart failure outcomes trials for this drug class, with DAPA-HF reporting positive results last year.
Reference
Wallach JD, Wang K, Zhang AD, et al. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. BMJ. 2020;368;l7078. doi: 10.1136/bmj.l7078.
Racial, Ethnic Disparities May Impact Age Differences at First Heart Failure Hospitalization
September 4th 2025Social determinants of health were associated with a younger age of first hospitalization for heart failure in Black and Hispanic patients when compared with Asian and White patients.
Read More
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
Patients With HFpEF May Benefit From Accelerated Cardiac Pacing
August 28th 2025In an observational extension of the myPACE clinical trial, researchers found that a personalized accelerated pacing in patients with heart failure with preserved ejection fraction (HFpEF) and a preexisting physiological pacer saw a slower trend in adverse cardiac events and overall improved health status.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Finerenone Demonstrates Safety and Efficacy in Heart Failure When Combined With Diuretics
August 13th 2025Clinical trial results establish the safety and efficacy of finerenone to help preserve potassium levels and reduce sodium in patients on diuretics with heart failure and mildly reduced ejection fraction or preserved ejection fraction.
Read More
Genetics, Comorbidities Associated With Cardiomyopathy and Atrial Fibrillation
August 13th 2025The cause of dilated cardiomyopathy (DCM) can be associated with the presence of the TTN gene combined with preexisting comorbidities like atrial fibrillation, which increase the odds of developing DCM.
Read More